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Abstract: 38 
Background: Tiotropium is a long acting antimuscarinic (LAMA), licenced as triple therapy 39 
with inhaled corticosteroid and long acting beta-agonist (ICS/LABA). There may be a 40 
synergistic benefit between LAMA and LABA as a consequence of receptor cross-talk, which 41 
in turn could modify beta-2 receptor down-regulation and associated tolerance induced by 42 
LABA.  43 
Objective: We hypothesise this mechanism may result in a reduction of airway 44 
hyperresponsiveness (AHR) when using triple therapy.  45 
Methods: We evaluated 14 non-smoking asthmatics using an open-label, randomized crossover 46 
design. ICS with Indacaterol and Tiotropium (IND/TIO) vs ICS with Indacaterol (IND) over 4 47 
weeks with challenge performed after 1st and last doses at trough.  48 
Results: We found no significant difference in mannitol sensitivity, expressed as the 49 
provocative dose of mannitol required to reach a 15% drop in FEV1, or mannitol reactivity, 50 
expressed as the response dose ratio (RDR: max % fall in FEV1 / cumulative dose ) , when 51 
comparing ICS/IND/TIO to ICS/IND. Geometric mean fold differences for RDR comparing 52 
single and chronic dosing were 3.26 fold (95%CI 1.46-7.29) and 2.51 fold (95%CI 1.32-4.79) 53 
for IND and IND/TIO respectively. Furthermore, salbutamol recovery post challenge was 54 
significantly blunted after chronic compared to single dosing with either IND (P<0.005) or 55 
IND/TIO (P<0.05).  56 
Conclusion & Clinical Relevance: Our data suggests that concomitant tiotropium does not 57 
modify the bronchoprotective tolerance induced by Indacaterol, in turn suggesting that cross-58 
talk may not be clinically relevant when using triple therapy. This study was registered on 59 
clinicaltrials.gov as NCT02039011. 60 
 61 
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Abbreviations: 73 
AHR: Airway hyperresponsiveness 74 
ACQ: Asthma control questionnaire 75 
AX: Reactance area under the curve 76 
FeNO: Exhaled nitric oxide 77 
ICS: Inhaled corticosteroid 78 
IND: Indacaterol 79 
IOS: Impulse oscillometry 80 
LABA: Long acting beta-2 agonist 81 
LAMA: Long acting muscarinic antagonist 82 
PD15: Provocative dose of mannitol required to reduce FEV1 by 15% 83 
RDR: Response dose ratio 84 
TIO: Tiotropium 85 
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Introduction 99 
 100 
Tiotropium (TIO) is a long acting muscarinic antagonist (LAMA), which is functionally 101 
selective for the post junctional M3 muscarinic receptor, found on airway smooth muscle [1]. 102 
TIO reduces asthma exacerbations by 21% in patients when used as add-on therapy in patients 103 
receiving inhaled corticosteroids and long-acting beta-agonists (ICS/LABA)[2]. Whilst 104 
blocking the M3 receptor inhibits acetylcholine induced bronchoconstriction, TIO exhibits only 105 
modest improvements in FEV1, which amounts to approximately 100ml at trough [2, 3] ,which 106 
is less than the minimally important difference of 230ml [4]. It is therefore hard to explain the 107 
protective effect on exacerbations on solely the basis of this small improvement in airway 108 
calibre alone [5].  109 
 110 
One mechanism by which TIO may exhibit its protective effects is by attenuating airway 111 
hyperresponsiveness (AHR), via blockade of the post junctional M3 muscarinic receptor, 112 
resulting in reduced response to cholinergic transmission [6]. M3, however, is not the only 113 
muscarinic receptor to contribute to increased airway tone and AHR; asthma is also associated 114 
with impaired pre-junctional M2 function [7] [8]. The pre-junctional M2 is an autoreceptor, as 115 
it is stimulated by acetylcholine to reduce further acetylcholine secretion. In asthma, the loss of 116 
this negative feedback mechanism results in increased AHR. Moreover, it has been postulated 117 
that both pre-junctional beta-2 and M2 receptors are inhibitory to the release of acetylcholine 118 
and that there is crosstalk between these receptor types [7, 8]. Hence it might be expected that 119 
chronic dosing with LABA might remove the brake to acetylcholine release as a consequence 120 
of down-regulation and subsensitivity of pre-junctional inhibitory beta-2 receptors, resulting in 121 
augmented cholinergic transmission and bronchoconstriction [7]. In this regard, TIO rapidly 122 
dissociates from M2 receptors, unlike its affinity for post junctional M3 receptors, thereby 123 
facilitating additional inhibition of M2 receptors and reduced pre-junctional acetylcholine 124 
release. This functional M3 selectivity may be a possible mechanism by which it reduces 125 
exacerbations in asthma by attenuating AHR [1].  126 
 127 
Another possible mechanism is that muscarinic M3 receptors promote beta-receptor 128 
desensitization through protein kinase C–mediated phosphorylation [9], hence inhibition of this 129 
effect by TIO may protect the beta-2 receptor from acetylcholine induced heterologous 130 
desensitization by acetylcholine[10]. In this regard looking at the converse situation, tiotropium 131 
has been shown to protect against propranolol induced bronchoconstriction [11].  132 
 133 
TIO may also reduce exacerbations via a putative anti-inflammatory action by inhibiting the 134 
paracrine effects of acetylcholine on inflammatory cells [12] . TIO has been shown to exhibit 135 
inhibitory effects on the development of airway remodelling in the animal model of antigen 136 
induced asthma[12, 13] . In vitro data have also suggested that there may be an anti-137 
inflammatory synergy between LABA and LAMA, via the cAMP pathway [9].  138 
 139 
Pointedly no studies have looked at effects of TIO on AHR assessed by bronchial challenge 140 
using non cholinergic agents. One study showed that as expected TIO produced prolonged 141 
functional antagonism of M3 mediated smooth muscle constriction induced by the cholinergic 142 
agonist methacholine [14]. As TIO is only currently indicated as add-on therapy to ICS/LABA 143 
[15], the objective of this study was to evaluate the impact of adding TIO to ICS/LABA on 144 
AHR, in patients with persistent asthma and whether TIO might also prevent against LABA 145 
induced subsensitivity[7]. We chose an indirect bronchial challenge, namely mannitol, as this 146 
is thought to more closely reflect physiological stimuli and acts by release of pro-inflammatory 147 
mediators [16]. Moreover mannitol challenge has been shown to be related to an inflammatory 148 
phenotype in asthma [17-19]. 149 
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 150 
Patients and Methods: 151 
Non-smoking male or female patients, aged at least 18 years, with persistent asthma already 152 
receiving ICS or ICS/LABA attended for a screening visit. Participants were recruited from the 153 
National Health Service (NHS Scotland) boards of Tayside and Fife, and also our existing 154 
database of asthma patients, at the Scottish Centre for Respiratory Research, in Ninewells 155 
Hospital & Medical School, Dundee, Scotland. Participants had to have a minimum FEV1 of 156 
>50% predicted and be mannitol responsive i.e. provocative dose required to reduce FEV1 by 157 
15% (PD15) <635mg, to be enrolled. Participants were also required to have no history of 158 
respiratory tract infection or oral corticosteroid use, in the last three months prior to screening. 159 
After initial screening, any LABA therapy was first withdrawn for 2 weeks followed by halving 160 
the ICS dose, to a minimum of 400µg/day (as beclometasone equivalent dose). If patients were 161 
on secondary controllers such as leukotriene receptor antagonists, these were also stopped. 162 
Participants then entered a 2 week run in on this dose of ICS, which was then continued 163 
throughout the study.   164 
The trial was a single centre, randomised open label cross-over design.  Patients received either 165 
4 weeks of indacaterol (Onbrez Breezhaler, Novartis, Calberley ,UK ) alone at a dose of 150µg 166 
OD (IND), or combined with tiotropium (Spiriva Handihaler, Boerhinger Ingelheim, Bracknell 167 
,UK  ) 18µg OD  (IND/TIO) as add-on to pre-existing ICS. There was a 2 week washout in 168 
between treatments while continuing to take the same dose of ICS. This washout was sufficient 169 
to minimise the possibility of carry-over effects of both IND and TIO [20].  170 
Including screening, there were 7 visits in total (figure 1.). Visits were performed, in the 171 
mornings, at baseline after run-in and washout, and at 24 hours (i.e. trough) after the first and 172 
last doses of each randomised treatment period. Patients were allowed short acting beta-2 173 
agonists (SABAs) as a reliever during the study, but were asked to abstain from SABA use at 174 
least 6 hours before each visit. The visits were conducted in the mornings (8am-10am). 175 
Participants were asked to record study medication use on a diary, and compliance was checked 176 
with returned empty capsule counts. This study was registered on clinicaltrials.gov as 177 
NCT02039011. The study was approved the Tayside committee for medical ethics (reference: 178 
13/ES/0072) and full informed consent was obtained from all patients. 179 
The primary outcome was mannitol challenge. This was performed as previously described[21] 180 
using a dry powder inhaler (Aridol Pharmaxis Ltd, Sydney, Australia) and increments up to a 181 
maximum cumulative dose of 635 mg. Mannitol sensitivity was expressed as the provocative 182 
dose of mannitol required to reach PD15, this was calculated by interpolation of the log-linear 183 
dose–response curve. The data for PD15 were log transformed before analysis. Mannitol 184 
reactivity was expressed as the response dose ratio (RDR) –i.e. maximum % fall in FEV1 185 
divided by the final mannitol dose. Impulse oscillometry, a secondary outcome, (Jaeger 186 
Masterscreen IOS, Hochberg, Germany) was performed as previously described [22] in 187 
triplicate, whilst subjects wore a nose clip, sealed lips tightly, and breathed quietly for 30 188 
seconds, in accordance with manufacturer’s guidelines. Resistance at 5 Hz (R5) and 20Hz 189 
(R20) is a measure of total and central airway resistance respectively, hence peripheral airway 190 
resistance was ascertained by the difference between R5 and R20. Lung compliance as its 191 
reciprocal reactance (X) and the area under the reactance curve (AX) was also measured. A 192 
SuperSpiro spirometer (Micro Medical Ltd, Chatham, Kent, United Kingdom) was used to 193 
perform spirometry in triplicate in accordance with European Respiratory  Society 194 
guidelines[23]. After mannitol challenge, salbutamol (400µg) was administered and 30 minute 195 
recovery recorded. Exhaled nitric oxide (FeNO) was performed using an NIOX MINO analyser 196 
(Aerocrine AB, Solna, Sweden), in accordance with the published guidelines [24]. Asthma 197 
control questionnaire (ACQ-7) was measured using the standard 7 point paper 198 
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questionnaire[25] (Qoltech, UK) . Randomisation was done with a computer generated code 199 
held by the Clinical Trials Pharmacy. 200 
Data Analysis  201 
The study was powered at 80% to detect a minimal important difference of one doubling dose 202 
in mannitol PD 15 (the primary outcome), as change from baseline, comparing indacaterol 203 
alone with indacaterol plus tiotropium, after single and chronic dosing, and a within-subject SD 204 
of 1.3 doubling dose, requiring a sample size of 14 using a crossover design, with alpha error 205 
of 0.05 (2 tailed). All data were first examined for normality and distribution. Repeated 206 
measures analysis of variance (ANOVA) was carried out assessing for treatment and sequence 207 
effects for the cross-over design. Where overall significance was found on ANOVA, 208 
Bonferroni corrected pairwise comparisons were then carried out. Thus, pairwise comparisons 209 
are reported as either significant (p<0.05, two-tailed) or not.  Statistical Analysis was done 210 
using IBM SPSS (version 22, IBM analytics, New York). 211 
Results: 212 
The participant flow for the trial is shown in the consort diagram (Figure 2), of the 39 patients 213 
screened 18 were randomised and 14 completed per protocol. Of the 14 ICS treated asthmatic 214 
patients analysed, 12 had at least one positive skin prick test to common aeroallergens,  mean 215 
age was 46 years , mean FEV1  86% predicted , mean BMI 30kg/m
2, mean R5 160% predicted 216 
, and mean ICS dose 693µg/day (beclometasone equivalent dose). No patients were current 217 
smokers, two were ex-smokers with a mean pack year history of 2.6. Values comparing mean 218 
ICS dose pre and post step down were 693 vs 429 µg/day (P< 0.05). 219 
Data for all outcomes according to study visits are summarised in Table 1. All outcome 220 
measures at first baseline and second baseline were assessed for carryover effect in order of 221 
sequence. There was no statistical difference between baseline data justifying the use of a 222 
pooled baseline value for comparison with randomised treatment arms. This confirmed an 223 
adequate washout period. In particular, there was no significant difference between mean 224 
baseline values for the primary outcome of mannitol PD15: 383mg vs 387 mg.  225 
There were significant improvements (P<0.05) in mannitol PD15 and RDR with IND or 226 
IND/TIO vs baseline after single but not chronic dosing (Figure 3). There was a significant 227 
difference (P<0.05) in RDR between single and chronic dosing for both treatments: geometric 228 
mean fold differences were 3.26 fold (95%CI 1.46-7.29) and 2.51 fold (95%CI 1.32-4.79) for 229 
IND and IND/TIO respectively. Furthermore, salbutamol recovery post challenge was 230 
significantly blunted after chronic compared to single dosing with either IND (P<0.005) or 231 
IND/TIO (P<0.05) (Figure 4 and table 1).  232 
 IOS measures including R5, R5-R20, and AX were all significantly improved (P<0.05) with 233 
both treatments compared to baseline after single and chronic dosing. FEV1 and FEF25-75 were 234 
significantly better after single dosing with both treatments (P<0.05) but only after chronic 235 
dosing with IND/TIO (P<0.05). There were no significant differences between treatments after 236 
chronic dosing for either mannitol AHR, spirometry or IOS outcomes. FeNO was unchanged 237 
with either treatment compared to baseline. ACQ was also unchanged by either treatment.  238 
Discussion: 239 
Our results showed improvements in mannitol AHR with both treatments after single dosing 240 
which were not maintained after repeated exposure, in addition to blunting of salbutamol 241 
recovery. This is likely to be indicative of agonist induced down-regulation and uncoupling of 242 
beta-2 receptors and associated tolerance of response .The loss of bronchoprotection induced 243 
7 
 
by indacaterol and associated cross tolerance seen as blunted  salbutamol recovery  has  244 
previously  been well documented  with other twice daily LABA’s in patients taking 245 
concomitant ICS [26-28] [29] [30]. Indacaterol has a high degree of intrinsic efficacy at the 246 
beta-2 receptor being 73% compared to the effect of isoprenaline in vitro.[31] In another study 247 
using isolated human bronchi the maximal relaxant response was 77% for indacaterol versus 248 
94% for formoterol [32]. In this regard prolonged stimulation with a high efficacy agonist like 249 
indacaterol would be expected to result in marked down regulation and uncoupling of beta-2 250 
receptors as has been previously shown with formoterol [28, 33-35].The loss of 251 
bronchoprotection was seen with indacaterol at 24 hours after the last dose at trough , when the 252 
airway might be particularly vulnerable to exogenous constrictor stimuli immediately prior to 253 
the next dose. The degree of bronchoprotection loss was the same with both treatments while 254 
chronic treatment with IND/TIO was no different compared to IND alone. Hence it can be 255 
concluded that we did not see any clinical evidence of crosstalk between muscarinic and beta-256 
2 receptors ,at least in terms of bronchoprotective subsensitivity using indirect challenge with 257 
mannitol [7]. The absence of any bronchoprotection seen with TIO is consistent with similar 258 
findings with ipratropium using direct acting histamine challenge [36] . In terms of the choice 259 
of challenge agent, mannitol was chosen as it is a well validated [37] indirect challenge and 260 
hence better reflects other physiological stimuli than direct challenges such as methacholine or 261 
histamine. Furthermore at the time of doing the study adenosine 5’ monophosphate (AMP) for 262 
human use was not commercially available. Whilst it is noted that response to mannitol is 263 
influenced by ICS [38], our patients had to be mannitol responsive at the first visit whilst taking 264 
a stable ICS dose, which remained constant throughout the study. Therefore we felt that any 265 
changes in mannitol AHR would only reflect the impact of bronchodilator treatments. 266 
Furthermore the PD15 and RDR values were not statistically different between first and second 267 
baseline, suggesting no carryover effects between randomised treatment arms.   268 
For IOS and spirometry, both treatments conferred improvements which were maintained after 269 
chronic dosing. As was the case with AHR, we found no significant differences in pulmonary 270 
function outcomes after chronic dosing comparing between IND/TIO and IND alone.  Previous 271 
studies in more severe patients have shown that TIO in addition to ICS/LABA results in 272 
approximately  100ml improvement in FEV1 [2], in turn suggesting that improved airway 273 
calibre per se is unlikely to be the explanation for reduced exacerbations[5] . We had originally 274 
considered that IOS might be more sensitive than spirometry at picking up subtle differences 275 
between double and triple therapy for bronchodilator effects measured at trough [39] [40].In 276 
the presence of a raised baseline R5 value of 160 % predicted, one might expect there to plenty 277 
of room for further improvement comparing double and triple therapy, which was not the case. 278 
Further studies are indicated to look at whether IOS is more sensitive to effects of TIO in more 279 
severe patients. 280 
There was no improvement in ACQ score, this reflecting the mean baseline value of 0.72 which 281 
is less than the 0.75 cut off value for optimal control[41] . However, the failure of add-on 282 
therapy with LAMA to improve ACQ scores was also seen by Peters et al in a much larger and 283 
more severe cohort [42]. FeNO was unchanged with either treatment, which could be explained 284 
by levels being already suppressed by concomitant ICS. Nonetheless, one would still expect 285 
the addition of TIO to have contributed to a modest further reduction from a mean baseline 286 
value of 30ppb, as shown in another study in more severe patients looking at triple therapy [43].  287 
The clinical relevance of our data is that when using triple therapy, at least in asthma, any 288 
effects of LAMA on exacerbations is unlikely to be due to bronchoprotective effects. Moreover 289 
concomitant LAMA does not mitigate tolerance induced by LABA or cross tolerance to 290 
salbutamol. Hence for patients taking ICS/LABA who might experience reduced protection 291 
against bronchoconstrictor stimuli, adding in a LAMA will not alleviate the situation, although 292 
it might conceivably still produce fewer exacerbations. The caveat is that our patients only had 293 
mild to moderate asthma and hence we did not see any significant additive bronchodilator 294 
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effects with LAMA. In other words if LAMA had produced altered airway geometry then 295 
perhaps we might have seen some additional bronchoprotection. Against this is the previous 296 
observation of Britton et al  where ipratropium did produce a dose related bronchodilator 297 
response which was disconnected from any effects on AHR to histamine challenge [36]. 298 
 299 
We accept that our study has limitations in that our patients were initially well controlled 300 
Moreover, our sample size was not powered to detect additional bronchodilation with TIO. As 301 
airway, geometry is an important determinant of bronchoprotection our negative findings with 302 
TIO on mannitol challenge might simply reflect the lack of additional bronchodilator effect 303 
with TIO. Although we did not have a comparator limb with TIO alone, one would have 304 
expected to see additive effects on AHR after chronic dosing when the bronchoprotective effect 305 
of LABA had diminished, in terms of there being room for potential further improvement after 306 
the last dose. One could always argue that TIO is only indicated for use as add-on to 307 
ICS/LABA, as was the case in the present study, and hence performing a study looking at TIO 308 
alone or in conjunction with ICS would have no clinical resonance. Finally, we acknowledge 309 
that we did not measure either sputum or blood eosinophils in the present study, although in 310 
that respect our patients were selected a priori on the basis of AHR. 311 
 312 
In conclusion, TIO did not modify the bronchoprotective tolerance induced by indacaterol or 313 
the cross tolerance seen on blunting of salbutamol recovery. Further studies perhaps involving 314 
bronchial biopsy might provide an insight into the putative anti-inflammatory action of TIO in 315 
asthma to help further elucidate the mechanism by which it reduces exacerbations in patients 316 
taking ICS/LABA. 317 
 318 
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Table 1. 548 
 INDACATEROL INDACATEROL + TIOTROPIUM 
 
 Pooled baseline Single dosing Chronic dosing Single dosing Chronic dosing 
FEV1 (L) 2.56 (2.18-2.95) 2.69 (2.28-3.10)* 2.64 (2.26-3.02) 2.78 (2.38-3.19)* 2.71 (2.33-3.09)* 
FEV1 percent 
predicted (%) 
87 (78-97) 91 (82-100)* 90 (81-100) 95 (85-105)* 93 (83-102)* 
FEF25-75 (L) 
 
1.79 (1.22-2.36) 2.02 (1.39-2.65)* 1.91 (1.25-2.57) 2.22 (1.49-2.95)* 1.94 (1.38-2.49)* 
R5 (kPa/l.s) 
 
0.54 (0.44-0.64) 0.45 (0.37-0.52)* 0.44 (0.37-0.50)* 0.39 (0.34-0.43)* 0.45(0.39-0.50)* 
R5-R20 (kPa/l.s) 
 
0.14 (0.07-0.22) 0.07 (0.03-0.11)* 0.07 (0.04-0.10)* 0.05 (0.03-0.07)* 0.08 (0.04-0.11)* 
AX (kPa/l) 
 
1.63 (0.58-2.68) 0.76 (0.34-1.19)* 0.68 (0.43-0.92)* 0.44 (0.25-0.63)* 0.78 (0.48-1.09)* 
RDR (%/mg) 
 
0.037 (0.025-
0.055) 
0.011 (0.005-
0.026)* 
0.037 (0.023-
0.061)† 
0.015 (0.008-
0.029)* 
0.035 (0.018-
0.070)† 
PD15 (mg) 
 
390 (291-521) 537 (438-619)* 455 (342-606) 487 (329-624)* 388 (255 -593) 
FENO (ppb) 
 
30 (20-45) 30 (20-44) 30 (20-45) 32 (23-45) 29 (19-44) 
Salbutamol 
Recovery 
(%.min) 
47 (-79 - 172) 33 (-47 – 113) 259 (196 – 322)* 77 (19-136) 239 (177-300)* 
ACQ7 0.72 (0.48-0.95)  0.44 (0.24-0.63)  0.50 (0.27-0.73) 
Values are presented as mean (95% CI) 
*Denotes significant (P<0.05) difference from pooled baseline. 
†Denotes significant difference (P<0.05) between single and chronic dosing within treatment groups.  
No statistically significant differences observed between Indacaterol vs Indacaterol + Tiotropium when comparing 
single vs chronic dosing at trough. Salbutamol recovery is expressed as the area under the curve (AUC) for 30 minutes.   
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Figure Legends  566 
 567 
 568 
Figure 1.  569 
Flowchart. 570 
 571 
Figure 2. 572 
Consort diagram. 573 
 574 
Figure 3. 575 
Effects of randomized treatments (as add on to ICS) compared to baseline on (a) mannitol 576 
sensitivity and (b) reactivity. P value denotes significant difference for randomised treatments 577 
compared to baseline. There was also a significant difference between single and chronic 578 
dosing for reactivity with both treatments. There were no differences between treatments. 579 
Values are geometric means and 95% CI. 580 
 581 
Figure 4. 582 
Effects of single and chronic dosing with either (a) indacaterol alone or (b) indacaterol 583 
+tiotropium (as add on to ICS) on salbutamol (400ug) recovery post challenge. P value 584 
denotes significant overall blunting of the salbutamol recovery comparing chronic vs single 585 
dosing. Values are means and SEM. 586 
 587 
